GlassScriptPhysician profile
Alexandre Rocha Abreu
NPI 1497710099
$33,918.63
in general payments reported to CMS, 2019-2025
9 companies · $1,216 in 2025
The $1,216 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $299 · 2021: $10K · 2022: $3,251 · 2023: $3,753 · 2024: $1,911 · 2025: $1,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,567 · Travel and Lodging: $1,195 · Consulting Fee: $700 · Education: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,566.88 |
| Travel and Lodging | $1,194.81 |
| Consulting Fee | $700.00 |
| Education | $417.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $28,531.57 | 2019-2025 | |
| Harmony Biosciences LLC | $2,146.09 | 2020-2025 | Wakix |
| Inspire Medical Systems, INC. | $1,435.27 | 2023 | Inspire |
| Axsome Therapeutics, INC. | $1,082.99 | 2022-2025 | Sunosi |
| Resmed Corp | $486.52 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $89.38 | 2022-2024 | Quviviq |
| Mallinckrodt Hospital Products INC. | $72.49 | 2022 | |
| Fisher & Paykel Healthcare INC | $38.16 | 2025 | Fisher & Paykel Healthcare |
| Lilly USA, LLC | $36.16 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandre Abreu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.